Answers are grounded in this paper and cite their sources.
Real-world data from four European regions show a decline in antithrombotic use driven by reduced low-dose aspirin, alongside stable or increasing statin use from 2010 to 2018.
Antithrombotic use in the UK, RSD, Udine and Spain declined between 2010 and 2018, driven by a reduction in use of low-dose aspirin that is not completely explained by a gradual increase in OAC use. Use of statins remained constant in the UK, and increased gradually in the RSD, Udine and Spain.
No takes yet. Share an insight, caveat, or question.
Rodrı́guez et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: